Quibim is a healthtech company pioneering the use of imaging biomarkers for precision medicine.

Quibim develops foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans. These insights enable precise characterization of phenotypes and prediction of outcomes in areas such as oncology, immunology, neurology and metabolic disorders. Quibim’s product portfolio includes four regulatory-cleared Medical Devices: QP-Prostate® to enhance prostate cancer detection; QP-Brain® for quantification of early brain atrophy and lesions; QP-Liver® a MR diagnosis of diffuse liver diseases; and QP-Insights®, a platform to manage, store and analyze multi-omics data in clinical trials and real-world data studies.

Healthcare institutions, research centers, hospitals, and clinical facilities are using Quibim products globally. Quibim has secured a global partnership with Philips to integrate its AI models into Philips’ MR scanners. In addition, Quibim has partnerships with Pharmaceutical companies, such as Merck KGaA, to enhance clinical trials and accelerate drug development with precise, actionable insights derived from imaging biomarkers.